Lorlatinib
Lorlatinib is a pharmaceutical drug with 50 clinical trials. Currently 18 active trials ongoing. Historical success rate of 70.0%.
Success Metrics
Based on 14 completed trials
Phase Distribution
Phase Distribution
10
Early Stage
17
Mid Stage
8
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
66.7%
14 of 21 finished
33.3%
7 ended early
18
trials recruiting
50
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC
Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Clinical Trials (50)
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC
Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma
PF-07284892 in Participants With Advanced Solid Tumors
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Induction Lorlatinib in Stage III Non-small Cell Lung Cancer
Lorlatinib Continuation Study
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 50